The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Dyskinesia Challenge, 2012The Effects of Memantine on Levodopa Induced Dyskinesias (LIDs) in MPTP-treated Pre-clinical Models
Objective/Rationale:
Levodopa is the mainstay of treatment for the motor symptoms of Parkinson’s disease. Unfortunately one of the long term side effects of levodopa treatment is the development of... -
Rapid Response Innovation Awards, 2012Functional Integration of Grafted Human Induced Neuronal (iN) Cells in Parkinson's Disease
Objective/Rationale:
Recently, genetic manipulation of human cells from various organs, e.g. skin, enabled direct generation of human nerve cells (so-called induced neurons – iNs) that potentially can... -
Rapid Response Innovation Awards, 2012Trace Amines and Their Metabolites as Potential Heraldic Markers in Parkinson’s Disease
Objective/Rationale:
Tools for early and unambiguous diagnosis of PD are currently missing and disease symptoms are easily mistaken. On the other hand, prompt recognition of PD subjects may increase... -
Rapid Response Innovation Awards, 2012Intestinal and Nasal Microbiota of Patients with Idiopathic Parkinson's disease
Objective/Rationale:
The cause of Parkinson’s disease is unknown and a reliable biomarker to identify Parkinson’s disease patients as early as possible is urgently needed. Nerve cells near the nose... -
Dyskinesia Challenge, 2012The Role of CK2 in the Development of Levodopa-Induced Dyskinesia in Parkinson’s disease
Promising Outcomes of Original Grant:
In Parkinson’s disease, dopamine-producing neurons degenerate, leading to a lack of dopamine in the brain. This leads to profound changes in the cells which are... -
Rapid Response Innovation Awards, 2012Enzymatic Degradation of Brain Complex Gangliosides to Increase Endogenous GM1 Levels: Potential Neuroprotective/Neurorestorative Therapy for Parkinson’s disease
Objective/Rationale:
Pre-clinical studies and clinical studies with GM1 ganglioside in Parkinson’s disease patients suggest potential symptomatic and disease modifying effects of GM1 on Parkinson’s...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.